1
|
Ibrahim MI, Alsafadi D, Safi E, Alenazi E, Aboulsoud M, Hussein MA, Alamry KA. Biosynthesized poly(3-hydroxybutyrate-co-3-hydroxyvalerate) as biocompatible microcapsules with extended release for busulfan and montelukast. Int J Biol Macromol 2022; 213:728-737. [PMID: 35671908 DOI: 10.1016/j.ijbiomac.2022.05.181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Revised: 05/09/2022] [Accepted: 05/27/2022] [Indexed: 11/18/2022]
Abstract
An extended release dosage form based on encapsulating the challenging drug busulfan within microspheres of the biodegradable, biocompatible and biosynthesized poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) polyester was achieved. The used (PHBV) polymer was biosynthesized by the halophilic archaeon Haloferax mediterranei from date waste biomass as feed-stock. PHBV microspheres of 1.2-2.1 μm diameter were successfully fabricated and loaded with busulfan with an encapsulation efficiency of 29.2 ± 0.2%. In addition, PHBV microspheres of 1.5-3.5 μm diameter and loaded with montelukast sodium (MK) drug were also fabricated with an encapsulation efficiency of 16.0 ± 0.4%. The double-emulsion solvent evaporation method was used to fabricate the drug-loaded microspheres. The drug-loaded microspheres have been characterized by XRD, FTIR and SEM, and confirmed to be successfully fabricated. The drugs in vitro release profiles have shown extended release for up to 3 days in case of busulfan and 8 h in case of montelukast sodium. The in vitro release profiles for busulfan and montelukast suggest that these drug-loaded microcapsules can be efficiently used as new dosage forms to solve the current issues of busulfan administration protocols, and to introduce a new dosage form for montelukast with extended release performance.
Collapse
Affiliation(s)
- Mohammad I Ibrahim
- Department of Chemistry, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - Diya Alsafadi
- Biocatalysis and Biosynthesis Research Unit, Advanced Research Center, Royal Scientific Society, Amman 11941, Jordan
| | - Eyad Safi
- College of Petroleum Engineering & Geosciences (CPG), King Fahd University of Petroleum & Minerals (KFUPM), Dhahran, Saudi Arabia
| | - Eid Alenazi
- King Faisal Specialist Hospital (KFSH), Riyadh, Saudi Arabia
| | | | - Mahmoud A Hussein
- Department of Chemistry, King Abdulaziz University, Jeddah 21589, Saudi Arabia; Polymer Chemistry Lab., Chemistry Department, Faculty of Science, Assiut University, Assiut 71516, Egypt
| | - Khalid A Alamry
- Department of Chemistry, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
| |
Collapse
|
2
|
Peviani M, Capasso Palmiero U, Cecere F, Milazzo R, Moscatelli D, Biffi A. Biodegradable polymeric nanoparticles administered in the cerebrospinal fluid: Brain biodistribution, preferential internalization in microglia and implications for cell-selective drug release. Biomaterials 2019; 209:25-40. [PMID: 31026609 DOI: 10.1016/j.biomaterials.2019.04.012] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2018] [Revised: 03/25/2019] [Accepted: 04/08/2019] [Indexed: 12/31/2022]
Abstract
Cell-selective drug release in the central nervous system (CNS) holds great promise for the treatment of many CNS disorders but it is still challenging. We previously demonstrated that polymeric nanoparticles (NPs) injected intra-parenchyma in the CNS can be internalized specifically in microglia/macrophages surrounding the injection site. Here, we explored NPs administration in the cerebrospinal fluid (CSF) to achieve a wider spreading and increased cell targeting throughout the CNS; we generated new NPs variants and studied the effect of modifying size and surface charge on NPs biodistribution and cellular uptake. Intra-cerebroventricular administration resulted in prevalent localization of the NPs in proximity to stem-cell niches, such as around the lateral ventricles, the subventricular zone and the rostral migratory stream. NPs internalization occurred preferentially in brain myeloid cells/microglia. We demonstrated that brain biodistribution and extent of internalization in microglia are influenced by NPs dimensions and can be improved by applying a transient disruption of the blood-brain barrier with mannitol, leading to NPs internalization in up to 25% of brain myeloid/microglia cells. A fraction of the targeted cells was positive for markers of proliferation or stained positive for stemness/progenitor-cell markers such as Nestin, c-kit, or NG2. Interestingly, through these newly formulated NPs we obtained controlled and selective release of drugs otherwise difficult to formulate (such as busulfan and etoposide) to the target cells, preventing unwanted side effects and the toxicity obtained by direct brain delivery of the not encapsulated drugs. Overall, these data provide proof of concept of the applicability of these novel NP-based drug formulations for achieving internalization not only in mature microglia but also possibly in more immature myeloid cells in the brain and pave the way for brain-restricted microglia-targeted drug delivery regimens.
Collapse
Affiliation(s)
- Marco Peviani
- Gene Therapy Program, Dana Farber/Boston Children's Cancer and Blood Disorders Center, 450 Brookline Ave., 02215, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; San Raffaele Telethon Institute for Gene Therapy, San Raffaele Scientific Institute, Via Olgettina 48, 20156, Milan, Italy.
| | - Umberto Capasso Palmiero
- Dipartimento di Chimica, Materiali ed Ingegneria Chimica, Politecnico di Milano, 20131, Milan, Italy; Institute for Chemical and Bioengineering, Department of Chemistry and Applied Biosciences, ETH Zürich, Vladimir-Prelog-Weg 1, 8093 Zürich, Switzerland
| | - Francesca Cecere
- San Raffaele Telethon Institute for Gene Therapy, San Raffaele Scientific Institute, Via Olgettina 48, 20156, Milan, Italy
| | - Rita Milazzo
- San Raffaele Telethon Institute for Gene Therapy, San Raffaele Scientific Institute, Via Olgettina 48, 20156, Milan, Italy
| | - Davide Moscatelli
- Dipartimento di Chimica, Materiali ed Ingegneria Chimica, Politecnico di Milano, 20131, Milan, Italy
| | - Alessandra Biffi
- Gene Therapy Program, Dana Farber/Boston Children's Cancer and Blood Disorders Center, 450 Brookline Ave., 02215, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; San Raffaele Telethon Institute for Gene Therapy, San Raffaele Scientific Institute, Via Olgettina 48, 20156, Milan, Italy.
| |
Collapse
|
3
|
Mathurin J, Pancani E, Deniset-Besseau A, Kjoller K, Prater CB, Gref R, Dazzi A. How to unravel the chemical structure and component localization of individual drug-loaded polymeric nanoparticles by using tapping AFM-IR. Analyst 2019; 143:5940-5949. [PMID: 30345433 DOI: 10.1039/c8an01239c] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
AFM-IR is a photothermal technique that combines AFM and infrared (IR) spectroscopy to unambiguously identify the chemical composition of a sample with tens of nanometer spatial resolution. So far, it has been successfully used in contact mode in a variety of applications. However, the contact mode is unsuitable for soft or loosely adhesive samples such as polymeric nanoparticles (NPs) of less than 200 nm of wide interest for biomedical applications. We describe here the theoretical basis of the innovative tapping AFMIR mode that can address novel challenges in imaging and chemical mapping. The new method enables gaining information not only on NP morphology and composition, but also reveals drug location and core-shell structures. Whereas up to now the locations of NP components could only be hypothesized, tapping AFM-IR allows accurately visualizing both the location of the NPs' shells and that of the incorporated drug, pipemidic acid. The preferential accumulation of the drug in the NPs' top layers was proved, despite its low concentration (<1 wt%). These studies pave the way towards the use of tapping AFM-IR as a powerful tool to control the quality of NP formulations based on individual NP detection and component quantification.
Collapse
Affiliation(s)
- Jérémie Mathurin
- Laboratoire de Chimie Physique (LCP), CNRS UMR 8000, Univ. of Paris-Sud, Université Paris-Saclay, 91405 Orsay, France.
| | | | | | | | | | | | | |
Collapse
|
4
|
Tawfik MA, Tadros MI, Mohamed MI. Lipomers (Lipid-polymer Hybrid Particles) of Vardenafil Hydrochloride: a Promising Dual Platform for Modifying the Drug Release Rate and Enhancing Its Oral Bioavailability. AAPS PharmSciTech 2018; 19:3650-3660. [PMID: 30291543 DOI: 10.1208/s12249-018-1191-0] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2018] [Accepted: 09/19/2018] [Indexed: 11/30/2022] Open
Abstract
Vardenafil hydrochloride is commonly used for the curing of erectile dysfunction. VAR suffers certain limitations: (i) short elimination half-life (4-5 h), (ii) low aqueous solubility (0.11 mg/mL), (iii) susceptibility to extensive first-pass metabolism and drug efflux transporters (P-glycoprotein), and (iv) limited (15%) oral bioavailability. The current study focused on the development of VAR lipomers as promising modified release systems able to enhance oral bioavailability. VAR-lipomers (lipid-polymer complexes) were successfully developed by a modified precipitation technique employing a lipid (polyglyceryl-6-distearate or glyceryl tristearate) and an amphiphilic polymer (Gantrez®). Three VAR:lipid ratios [1:1, 1:2, and 1:3] and three VAR:Gantrez® ratios [4:1, 2:1, and 1:1] were investigated. Solid-state characterization studies involved differential scanning calorimetry (DSC), X-ray diffraction (XRD), and Fourier-transform infrared (FT-IR) spectroscopy. The systems were assessed for particle size, polydispersity index (PDI), zeta-potential, VAR entrapment-efficiency (EE%), morphology, and VAR released % after 2 h (Q2h) and 8 h (Q8h). The best-achieved system (the highest desirability) was promoted for pharmacokinetic studies in fasted rabbits. Statistical analysis of data revealed that L9 system (PGDS, VAR, and Gantrez®; 3:1:1, respectively) had the highest desirability (0.85) with respect to spherical particle size (622.15 nm), PDI (0.11), zeta-potential (-27.90 mV), EE% (62.80%), Q2h (43.45%), and Q8h (77.40%). With respect to Levitra® tablets, the significantly higher relative bioavailability (170%), delayed Tmax, and extended MRT(0-∞) clarified the dual ability of L9 system. Lipomers are emerging systems capable of modifying the rate of VAR release and promoting its oral bioavailability.
Collapse
|
5
|
Pancani E, Menendez-Miranda M, Pastor A, Brisset F, Bernet-Camard MF, Desmaële D, Gref R. Nanoparticles with high payloads of pipemidic acid, a poorly soluble crystalline drug: drug-initiated polymerization and self-assembly approach. Acta Pharm Sin B 2018; 8:420-431. [PMID: 29881681 PMCID: PMC5989915 DOI: 10.1016/j.apsb.2018.03.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2018] [Revised: 02/28/2018] [Accepted: 03/16/2018] [Indexed: 01/03/2023] Open
Abstract
Nowadays, biodegradable polymers such as poly(lactic acid) (PLA), poly(D,L-lactic-co-glycolic acid) (PLGA) and poly(ε-caprolactone) (PCL) remain the most common biomaterials to produce drug-loaded nanoparticles (NPs). Pipemidic acid (PIP) is a poorly soluble antibiotic with a strong tendency to crystallize. PIP incorporation in PLA/PLGA NPs was challenging because of PIP crystals formation and burst release. As PIP had a poor affinity for the NPs, an alternative approach to encapsulation was used, consisting in coupling PIP to PCL. Thus, a PCL-PIP conjugate was successfully synthesized by an original drug-initiated polymerization in a single step without the need of catalyst. PCL-PIP was characterized by NMR, IR, SEC and mass spectrometry. PCL-PIP was used to prepare self-assembled NPs with PIP contents as high as 27% (w/w). The NPs were characterized by microscopy, DLS, NTA and TRPS. This study paves the way towards the production of NPs with high antibiotic payloads by drug-initiated polymerization. Further studies will deal with the synthesis of novel polymer-PIP conjugates with ester bonds between the drug and PCL. PIP can be considered as a model drug and the strategy developed here could be extended to other challenging antibiotics or anticancer drugs and employed to efficiently incorporate them in NPs.
Collapse
Affiliation(s)
- Elisabetta Pancani
- Institut de Sciences Moléculaires d’Orsay (ISMO), Univ. of Paris-Sud, Université Paris-Saclay, Orsay 91405, France
| | - Mario Menendez-Miranda
- Institut de Sciences Moléculaires d’Orsay (ISMO), Univ. of Paris-Sud, Université Paris-Saclay, Orsay 91405, France
| | - Alexandra Pastor
- Institut de Sciences Moléculaires d’Orsay (ISMO), Univ. of Paris-Sud, Université Paris-Saclay, Orsay 91405, France
- Institut Galien, UMR8612 Univ. of Paris-Sud, Université Paris-Saclay, Châtenay-Malabry 92290, France
| | - François Brisset
- Institut de Chimie Moléculaire et des Matériaux d'Orsay (ICMMO), Univ. of Paris-Sud, Université Paris-Saclay, Orsay 91405, France
| | - Marie-Françoise Bernet-Camard
- EA4043 "Unité Bactéries Pathogènes et Santé" (UBaPS), Univ. of Paris-Sud, Université Paris-Saclay, Châtenay-Malabry 92290, France
| | - Didier Desmaële
- Institut Galien, UMR8612 Univ. of Paris-Sud, Université Paris-Saclay, Châtenay-Malabry 92290, France
| | - Ruxandra Gref
- Institut de Sciences Moléculaires d’Orsay (ISMO), Univ. of Paris-Sud, Université Paris-Saclay, Orsay 91405, France
| |
Collapse
|
6
|
Chobisa D, Patel K, Monpara J, Patel M, Vavia P. Development and characterization of an organic solvent free, proliposomal formulation of Busulfan using quality by design approach. Int J Pharm 2018; 535:360-370. [DOI: 10.1016/j.ijpharm.2017.11.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2017] [Revised: 10/27/2017] [Accepted: 11/03/2017] [Indexed: 10/18/2022]
|
7
|
Costa-Gouveia J, Pancani E, Jouny S, Machelart A, Delorme V, Salzano G, Iantomasi R, Piveteau C, Queval CJ, Song OR, Flipo M, Deprez B, Saint-André JP, Hureaux J, Majlessi L, Willand N, Baulard A, Brodin P, Gref R. Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. Sci Rep 2017; 7:5390. [PMID: 28710351 PMCID: PMC5511234 DOI: 10.1038/s41598-017-05453-3] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Accepted: 05/24/2017] [Indexed: 12/15/2022] Open
Abstract
Tuberculosis (TB) is a leading infectious cause of death worldwide. The use of ethionamide (ETH), a main second line anti-TB drug, is hampered by its severe side effects. Recently discovered "booster" molecules strongly increase the ETH efficacy, opening new perspectives to improve the current clinical outcome of drug-resistant TB. To investigate the simultaneous delivery of ETH and its booster BDM41906 in the lungs, we co-encapsulated these compounds in biodegradable polymeric nanoparticles (NPs), overcoming the bottlenecks inherent to the strong tendency of ETH to crystallize and the limited water solubility of this Booster. The efficacy of the designed formulations was evaluated in TB infected macrophages using an automated confocal high-content screening platform, showing that the drugs maintained their activity after incorporation in NPs. Among tested formulations, "green" β-cyclodextrin (pCD) based NPs displayed the best physico-chemical characteristics and were selected for in vivo studies. The NPs suspension, administered directly into mouse lungs using a Microsprayer®, was proved to be well-tolerated and led to a 3-log decrease of the pulmonary mycobacterial load after 6 administrations as compared to untreated mice. This study paves the way for a future use of pCD NPs for the pulmonary delivery of the [ETH:Booster] pair in TB chemotherapy.
Collapse
MESH Headings
- Administration, Inhalation
- Animals
- Antitubercular Agents/pharmacology
- Disease Models, Animal
- Drug Carriers
- Drug Compounding/methods
- Drug Synergism
- Drug Therapy, Combination/methods
- Ethionamide/pharmacology
- Female
- Humans
- Mice
- Mice, Inbred BALB C
- Mycobacterium tuberculosis/drug effects
- Mycobacterium tuberculosis/growth & development
- Mycobacterium tuberculosis/pathogenicity
- Nanoparticles/administration & dosage
- Nanoparticles/chemistry
- Oxadiazoles/pharmacology
- Piperidines/pharmacology
- Polylactic Acid-Polyglycolic Acid Copolymer/chemistry
- RAW 264.7 Cells
- Solubility
- Treatment Outcome
- Tuberculosis, Multidrug-Resistant/drug therapy
- Tuberculosis, Multidrug-Resistant/microbiology
- Tuberculosis, Multidrug-Resistant/pathology
- Tuberculosis, Pulmonary/drug therapy
- Tuberculosis, Pulmonary/microbiology
- Tuberculosis, Pulmonary/pathology
- beta-Cyclodextrins/chemistry
Collapse
Affiliation(s)
- Joana Costa-Gouveia
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France
| | - Elisabetta Pancani
- University of Paris-Sud, University Paris-Saclay, CNRS, UMR 8214 - Institute for Molecular Sciences of Orsay (ISMO), 91405, Orsay, France
| | - Samuel Jouny
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France
| | - Arnaud Machelart
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France
| | - Vincent Delorme
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France
| | - Giuseppina Salzano
- University of Paris-Sud, University Paris-Saclay, CNRS, UMR 8214 - Institute for Molecular Sciences of Orsay (ISMO), 91405, Orsay, France
| | - Raffaella Iantomasi
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France
| | - Catherine Piveteau
- Univ. Lille, INSERM, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000, Lille, France
| | - Christophe J Queval
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France
| | - Ok-Ryul Song
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France
| | - Marion Flipo
- Univ. Lille, INSERM, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000, Lille, France
| | - Benoit Deprez
- Univ. Lille, INSERM, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000, Lille, France
| | | | - José Hureaux
- University Hospital Center of Angers, 49000, Angers, France
| | - Laleh Majlessi
- Pathogénomique Mycobactérienne Intégrée, Département de Génomes et Génétique, Institut Pasteur, Paris, France
| | - Nicolas Willand
- Univ. Lille, INSERM, Institut Pasteur de Lille, U1177 - Drugs and Molecules for living Systems, F-59000, Lille, France
| | - Alain Baulard
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France
| | - Priscille Brodin
- Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France.
| | - Ruxandra Gref
- University of Paris-Sud, University Paris-Saclay, CNRS, UMR 8214 - Institute for Molecular Sciences of Orsay (ISMO), 91405, Orsay, France.
| |
Collapse
|
8
|
Ćurić A, Möschwitzer JP, Fricker G. Development and characterization of novel highly-loaded itraconazole poly(butyl cyanoacrylate) polymeric nanoparticles. Eur J Pharm Biopharm 2017; 114:175-185. [PMID: 28159723 DOI: 10.1016/j.ejpb.2017.01.014] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2016] [Revised: 01/20/2017] [Accepted: 01/24/2017] [Indexed: 01/02/2023]
Abstract
Treatment of cryptococcal meningitis with antifungals such as itraconazol is difficult due their low concentration in the brain. Therefore, drug carriers with high payload are highly desired. But, generation of itraconazole loaded poly(butyl cyanoacrylate) nanoparticles with higher drug load, for instance more than 20% drug, is challenging. In present study we were able to generate novel highly loaded itraconazole poly(butyl cyanoacrylate) nanocapsules containing up to 99% (w/w) itraconazole and 1% polymer (w/w). Moreover, a controllable manufacturing procedure using a one-step emulsion solvent evaporation technique was established in order to discriminate between itraconazole loaded nanocapsules and nanospheres. Furthermore, it could be demonstrated that our novel nanocapsules can be decorated with targeting molecules such as apolipoprotein E. More precisely, apolipoprotein E was covalently bound to a maleimide linker, which was integrated within the surface of polymeric nanoparticle. This covalent binding of apolipoproteinE to the surface of a drug delivery system enables targeting of low density lipoprotein receptor (LDLR) expressed on endothelial brain capillary cell membranes, making our novel highly loaded itraconazole poly(butyl cyanoacrylate) nanocapsules a promising drug delivery system for treatment of cryptococcal meningitis.
Collapse
Affiliation(s)
- Anamarija Ćurić
- AbbVie Deutschland GmbH & Co. KG, Knollstraße, 67061 Ludwigshafen, Germany; Ruprecht-Karls University, Institute of Pharmacy & Molecular Biotechnology, Im Neuenheimer Feld 329, 69120 Heidelberg, Germany
| | - Jan Peter Möschwitzer
- Advance Pharma GmbH, Wallenroder Straße 12-14, 13435 Berlin, Germany; AbbVie Deutschland GmbH & Co. KG, Knollstraße, 67061 Ludwigshafen, Germany
| | - Gert Fricker
- Ruprecht-Karls University, Institute of Pharmacy & Molecular Biotechnology, Im Neuenheimer Feld 329, 69120 Heidelberg, Germany.
| |
Collapse
|
9
|
Development and lyophilization of itraconazole loaded poly(butylcyanoacrylate) nanospheres as a drug delivery system. Eur J Pharm Sci 2015; 78:121-31. [DOI: 10.1016/j.ejps.2015.07.010] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2015] [Revised: 07/06/2015] [Accepted: 07/09/2015] [Indexed: 11/18/2022]
|
10
|
Benival DM, Devarajan PV. Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability. Int J Pharm 2012; 423:554-61. [DOI: 10.1016/j.ijpharm.2011.11.035] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2011] [Revised: 11/23/2011] [Accepted: 11/23/2011] [Indexed: 10/14/2022]
|
11
|
Chalati T, Horcajada P, Couvreur P, Serre C, Ben Yahia M, Maurin G, Gref R. Porous metal organic framework nanoparticles to address the challenges related to busulfan encapsulation. Nanomedicine (Lond) 2011; 6:1683-95. [DOI: 10.2217/nnm.11.69] [Citation(s) in RCA: 85] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Busulfan is an alkylating agent widely used in chemotherapy, but with severe side effects. Many attempts have been made to entrap busulfan in nanocarriers to avoid liver accumulation and to protect it against rapid degradation in aqueous media. However, poor loadings (≤5 wt%) and fast release were generally obtained due to the low affinity of busulfan towards the nanocarriers. Moreover, drug crystallization often occurred during nanoparticle preparation. To circumvent these drawbacks, metal organic framework (MOF) nanoparticles, based on crystalline porous iron (III) carboxylates, have shown an unprecedented loading (up to 25 wt%) of busulfan. This was attributed to the high porosity of nanoMOFs as well as to their hydrophilic–hydrophobic internal microenvironment well adapted to the amphiphilic character of busulfan. NanoMOFs formulations have kept busulfan in molecular form, preventing its crystallization and degradation. Indeed, busulfan was released intact, as proved by the maintenance of its pharmacological activity.
Collapse
Affiliation(s)
- T Chalati
- Faculté de Pharmacie (UMR CNRS 8612), Université Paris-Sud, 92296 Châtenay-Malabry Cedex, France
| | | | - P Couvreur
- Faculté de Pharmacie (UMR CNRS 8612), Université Paris-Sud, 92296 Châtenay-Malabry Cedex, France
| | - C Serre
- Institut Lavoisier (UMR CNRS 8180), Université de Versailles, 78035 Versailles Cedex, France
| | - M Ben Yahia
- Institut Charles Gerhardt Montpellier (UMR CNRS 5253), Université Montpellier 2, 34095 Montpellier cedex 05, France
| | - G Maurin
- Institut Charles Gerhardt Montpellier (UMR CNRS 5253), Université Montpellier 2, 34095 Montpellier cedex 05, France
| | | |
Collapse
|
12
|
The application of MALDI TOF MS in biopharmaceutical research. Int J Pharm 2011; 417:70-82. [DOI: 10.1016/j.ijpharm.2010.12.010] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2010] [Revised: 12/05/2010] [Accepted: 12/06/2010] [Indexed: 12/21/2022]
|
13
|
Abstract
In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, in particular antibodies. Antibody–nanoparticle conjugates have the potential to elicit effective targeting and release of therapeutic targets at the disease site, while minimizing off-target side effects caused by dosing of normal tissues. This article provides an overview of various antibody-conjugated nanoparticle strategies, focusing on the rationale of cell-surface receptors targeted and their potential clinical application.
Collapse
Affiliation(s)
- Francois Fay
- School of Pharmacy, Queen’s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast, BT9 7BL, UK
| | | |
Collapse
|
14
|
Polyethylene sebacate–doxorubicin nanoparticles for hepatic targeting. Int J Pharm 2010; 401:113-22. [DOI: 10.1016/j.ijpharm.2010.09.012] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2010] [Revised: 09/09/2010] [Accepted: 09/14/2010] [Indexed: 11/22/2022]
|
15
|
Bouligand J, Couvreur P, Layre AM, Deroussent A, Paci A, Delain E, Vassal G, Gref R. Busulphan-loaded long-circulating nanospheres, a very attractive challenge for both galenists and pharmacologists. J Microencapsul 2008; 24:715-30. [DOI: 10.1080/02652040701500905] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
16
|
Vauthier C, Labarre D, Ponchel G. Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery. J Drug Target 2008; 15:641-63. [PMID: 18041633 DOI: 10.1080/10611860701603372] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Poly(alkylcyanoacrylate) (PACA) nanoparticles were first developed 25 years ago taking advantage of the in vivo degradation potential of the polymer and of its good acceptance by living tissues. Since then, various PACA nanoparticles were designed including nanospheres, oil-containing and water-containing nanocapsules. This made possible the in vivo delivery of many types of drugs including those presenting serious challenging delivery problems. PACA nanoparticles were proven to improve treatments of severe diseases like cancer, infections and metabolic disease. For instance, they can transport drugs across barriers allowing delivery of therapeutic doses in difficult tissues to reach including in the brain or in multidrug resistant cells. This review gives an update on the more recent developments and achievements on design aspects of PACA nanoparticles as delivery systems for various drugs to be administered in vivo by different routes of administration.
Collapse
|